Peter Marks, director of Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research noted that “vaccination remains critical to public health and continued protection against serious consequences of Covid-19, including hospitalization and death.” But what is the protection for those Americans who can’t take the vaccine?
Improving The FDA’s Regulatory Process Can Enhance Treatment Options
People who are immunocompromised are disproportionately impacted by diseases such as Covid-19. They are at higher risk of experiencing more serious illnesses and at higher risk of dying. Unfortunately, they also receive less protections from standard vaccines assuming they can even take them.
Given these realities, the regulatory environment should facilitate a wider array of treatment options. Unfortunately, in the fight against the mutating Covid-19 virus, we continue to lose important options.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.